TY - JOUR
T1 - Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015
AU - Thompson, Philip A.
AU - Kantarjian, Hagop M.
AU - Cortes, Jorge E.
N1 - Publisher Copyright:
© 2015 Mayo Foundation for Medical Education and Research.
PY - 2015/10
Y1 - 2015/10
N2 - Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.
AB - Few neoplastic diseases have undergone a transformation in a relatively short period like chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer in which a unique chromosomal abnormality was identified and a pathophysiologic correlation suggested. Landmark work followed, recognizing the underlying translocation between chromosomes 9 and 22 that gave rise to this abnormality and, shortly afterward, the specific genes involved and the pathophysiologic implications of this novel rearrangement. Fast forward a few years and this knowledge has given us the most remarkable example of a specific therapy that targets the dysregulated kinase activity represented by this molecular change. The broad use of tyrosine kinase inhibitors has resulted in an improvement in the overall survival to the point where the life expectancy of patients today is nearly equal to that of the general population. Still, there are challenges and unanswered questions that define the reasons why the progress still escapes many patients, and the details that separate patients from ultimate cure. In this article, we review our current understanding of CML in 2015, present recommendations for optimal management, and discuss the unanswered questions and what could be done to answer them in the near future.
UR - http://www.scopus.com/inward/record.url?scp=84955415070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955415070&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2015.08.010
DO - 10.1016/j.mayocp.2015.08.010
M3 - Review article
C2 - 26434969
AN - SCOPUS:84955415070
SN - 0025-6196
VL - 90
SP - 1440
EP - 1454
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 10
ER -